Sézary syndrome associated with granulomatous lesions during treatment with bexarotene.
Sézary syndrome (SS) is a leukaemic variant of cutaneous T-cell lymphoma (CTCL). We report a patient with SS who developed granulomatous lesions. These lesions broke out during treatment with bexarotene when the disease had appeared to stabilize. After a partial clinical remission the disease showed rapid progression and finally led to the patient's death. This contradicts the initial assessment, which considered the granulomatous inflammation as a good prognostic factor in CTCL.
Ruiz-de-Casas
A
A
Department of Dermatology, Virgen Macarena University Hospital, Seville, Spain. aruizdecasas@aedv.es
Carrizosa-Esquivel
A
A
Herrera-Saval
A
A
Rios-Martín
J J
JJ
Camacho
F
F
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000077610:Bexarotene; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D017809:Fatal Outcome; D005260:Female; D006099:Granuloma / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D012751:Sezary Syndrome / Q000188:drug therapy*; D013764:Tetrahydronaphthalenes / Q000009:adverse effects*
D000970:Antineoplastic Agents; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene